非小细胞肺癌中microRNAs与EGFR-TKIs继发性耐药机制的研究进展

摘要

近年来，在非小细胞肺癌（non-small cell lung cancer, NSCLC）靶向治疗中，尤其是伴有表皮生长因子受体（epidermal growth factor receptor,EGFR）基因突变的患者，EGFR酪氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）越来越多地进入到临床治疗，但EGFR-TKI耐药的产生不仅影响药物敏感性，甚至出现疾病进展，成为制约其疗效的主要瓶颈。微小RNA（microRNAs, miRNAs）是一种非编码蛋白的RNA，参与转录后水平基因的表达调控，最近研究发现，miRNAs参与了EGFR-TKIs耐药，影响肿瘤细胞对吉非替尼的敏感性。本文就NSCLC中miRNAs与EGFR-TKIs继发性耐药之间的相关性研究进展做简要的综述。%In recent years, in non-small cell lung cancer (NSCLC) targeted therapy, especially in patients with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKI) more and more come into the clinical treatment, but EGFR-TKI resistance not only inlfuence the drug sensitivity, appear even disease progression, become the main bottleneck of its curative effect. MicroRNAs (miRNAs) is a non coding RNA and protein involved in regulating gene expression in the transcription level. Recent studies found that miRNAs involved in EGFR-TKIs resistance, which affect the sensitivity of tumor cells to treatment. In this paper, we reviewed brielfy advance in miRNAs and EGFR-TKIs secondary resis-tance research in NSCLC.